Charactertistic | Antiretroviral naïve (N = 155) | Antiretroviral experienced (N = 883) | ||
---|---|---|---|---|
(quantitative) | Mean | SD | Mean | SD |
Age (years) | 38.86 | 6.47 | 38.91 | 5.44 |
Nadir CD4+ (cells/μl) | 185.02 | 115.79 | 159.99 | 131.80 |
CD4+ T-cell count at baseline (cells/μl) | 206.75 | 133.53 | 357.88 | 233.05 |
HIV-RNA at baseline (copies/ml) | 177,480 | 252,619 | 53,615 | 168,410 |
ALT at baseline (x10 IU/l) | 6.94 | 4.14 | 7.13 | 4.42 |
AST at baseline (x10 IU/l) | 6.27 | 3.88 | 5.87 | 3.94 |
CD4+ T-cell slope (cells/μl) | 107.86 | 116.37 | 44.30 | 149.48 |
Exposure to DDX-drugs at baseline (days) | - | - | 1,288 | 1,075 |
(qualitative) | N | % | N | % |
Gender (male) | 113 | 72.90 | 677 | 76.67 |
Risk factor for HIV acquisition (former IVDU) | 105 | 67.74 | 684 | 77.46 |
HBsAg positivity | 15 | 10.27 | 55 | 6.48 |
HDVAb positivity | 4 | 2.96 | 25 | 2.83 |
Previous grade ≥III LFT elevation | 15 | 9.68 | 317 | 35.90 |
Previous treatment with IFN | 7 | 4.52 | 72 | 8.15 |
Concurrent use of DDX-drugs | 50 | 32.26 | 526 | 59.57 |
Concurrent use of 3TC | 138 | 89.03 | 618 | 69.99 |
Concurrent use of TDF | 17 | 18.97 | 136 | 15.40 |
Treatment group (Single PI) | 32 | 20.64 | 202 | 22.88 |
NFV | 27 | 84.38 | 147 | 72.77 |
IDV | 2 | 6.25 | 32 | 15.84 |
SQV | 3 | 9.37 | 19 | 9.41 |
Others | - | - | 4 | 1.98 |
Treatment group (Multiple PI) | 50 | 32.26 | 322 | 36.47 |
LPV/r | 42 | 84 | 175 | 54.35 |
IDV/r | 5 | 10 | 83 | 25.78 |
SQV/r | 1 | 2 | 48 | 14.91 |
Others | 2 | 4 | 16 | 4.96 |
Treatment group (NNRTI) | 73 | 47.10 | 359 | 41.62 |
EFV | 42 | 57.53 | 165 | 45.96 |
NVP | 31 | 42.47 | 194 | 54.04 |